13.1 Haematology Values and Change from Baseline over Time • Table 14.3. 14.1 Biochemistry Values and Change from Baseline over Time • Table 14.3. 16.1 Summary of ECOG Performance Status over Time • Figure 14.2.1.1 Kaplan -Meier Plot of Disease- free Survival (DFS1) (ATP) • Figure 14.2.2.1 Kaplan -Meier Plot of Disease- free Survival (DFS2) (ATP) • Figure 14.2. 3.1 Kaplan- Meier Plot of Overall Survival (OS1) (ATP) • Figure 14.2. 4.1 Kaplan- Meier Plot of Over all Survival (OS2) (ATP) • Figure 14.2. 5 Swimmer Plot of Disease -free Survival (DFS1) and Overall Survival (OS1) • Figure 14.2. 6 Swimmer Plot of Disease -free Survival (DFS2) and Overall Survival (OS2) When 1- year data is available for the Modified vaccination group and the Main and Concomitant groups have completed the study, a full set of TFLs will be produced based on all available data at that point. 6.6 Archival Listings Investigator comments will be listed for all treated patients. Syne qua non study no: TAX12001 Targovax ASA study no: CT TG01 -01 Date: 02MAY2018 Page 21 of 21 Version: Amendment 1.0 Final 1.0 ST/form/010/10 Statistical programming output used in preparing survival analysis will be provided in the archival output. 7 REFERENCES Oettle H, Post S, Neuhaus P, Gell ert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative- intent resection of pancreatic cancer: a randomized controlled trial. JAMA.